Real-world datasets that include patients who were not treated on clinical trials may identify that the incidence of irAEs is much higher than reported in clinical trials.23 Our rates of irAEs were similar to a recent real-world cohort of patients with melanoma (n = 135), renal cell carcinoma (n = 44), and NSCLC (n = 38) who survived more than 2 years post ICI (anti-PD-(L)1 or anti-CTLA) start.24 In this study, the incidence of acute irAEs was 65%, and chronic irAEs were up to 49%. This evidence concerns the gene CD274 and renal cell carcinoma.